2

Influence of CYP2C8, CYP3A4 and CYP3A5 host genotypes on early recurrence of Plasmodium vivax [Mechanisms of Resistance]

CYP450 enzymes are involved in biotransformation of chloroquine (CQ), but the role of the different metabolism profiles of this drug has not been properly investigated in relation to P. vivax recurrences. To investigate the influence of CYPs genotypes associated with CQ-metabolism on early recurrence rates of P. vivax, a case-control study was carried out. Cases included patients presenting an early recurrence (CQ-recurrent), defined as recurrence during the first 28 days after initial infection, plasma concentrations of CQ plus desethylchloroquine (DCQ, the major CQ metabolite) higher than 100 ng/mL. A control (CQ-responsive) with no parasite recurrence over the follow-up was also included. CQ and DCQ plasma levels were measured on Day 28. CQ CYPs (CYP2C8, CYP3A4 and CYP3A5) genotypes were determined by real-time PCR. An ex vivo study was conducted to verify CQ and DCQ efficacy in P. vivax isolates. The frequency of alleles associated with normal and slow metabolism was similar between the cases and controls for CYP2C8 (OR=1.45, 95% CI=0.51-4.14, p=0.570), CYP3A4 (OR=2.38, 95% CI=0.92-6.19, p=0.105) and CYP3A5 (OR=4.17, 95% CI=0.79-22.04, p=1.038) genes. DCQ levels were higher than CQ, regardless of the genotype. Regarding the DCQ/CQ rate, there was no difference between groups or between those patients who had a normal or mutant genotype. DCQ and CQ showed similar efficacy ex vivo. CYPs genotypes had no influence on early recurrence rates. Similar efficacy of CQ and DCQ ex vivo could explain the absence of therapeutic failure, despite presence of alleles associated with slow metabolism.




2

Comparative Genomic Analysis of Third Generation Cephalosporin-Resistant Escherichia coli Harboring blaCMY-2-Positive IncI1 group, IncB/O/K/Z, and IncC Plasmids Isolated from Healthy Broilers in Japan. [Epidemiology and Surveillance]

The off-label use of third generation cephalosporin (3GC) during in ovo vaccination or vaccination of newly hatched chicks, was a common practice worldwide. CMY-2-producing Escherichia coli have been disseminated among broiler production. The objectives of this study were to determine the epidemiological linkage of blaCMY-2-positive plasmids among broilers both within and outside Japan because grandparent stock and parent stock were imported in Japan. We examined the whole genome sequences of 132 3GC-resistant E. coli isolates collected from healthy broilers during 2002-2014. The predominant 3GC-resistance gene was blaCMY-2, which was detected in the plasmids of 87 (65.9%) isolates. The main plasmid replicon types were IncI1-I (n=21; 24.1%), IncI (n=12; 13.8%), IncB/O/K/Z (n=28; 32.2%), and IncC (n=22; 25.3%). Those plasmids were subjected to gene clustering and network analyses and plasmid multi-locus sequence typing (pMLST). The chromosomal DNA of isolates was subjected to MLST and single nucleotide variant (SNV)-based phylogenetic analysis.

MLST and SNV-based phylogenetic analysis revealed high diversity of E. coli isolates. ST429 harboring blaCMY-2-positive IncB/O/K/Z was closely related to isolates from broiler in Germany harboring blaCMY-2-positive IncB/O/K/Z. pST55-IncI and pST12-IncI1-I and pST3-IncC were prevalent in western Japan. pST12-IncI1-I and pST3-IncC were closely related to those detected in E. coli isolates from chicken in American continent, whereas 26 IncB/O/K/Z were related to those in Europe. These data will be useful to reveal the whole picture of transmission of CMY-2-producing bacteria in and out of Japan.




2

Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025) [Antiviral Agents]

Cyclophilins play a key role in the lifecycle of coronaviruses. Alisporivir (Debio 025) is a non-immunosuppressive analogue of cyclosporin A with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in VeroE6 cell line, with an EC50 of 0.46±0.04 μM. Alisporivir inhibited a post-entry step of the SARS-CoV-2 lifecycle. These results justify that a proof-of-concept Phase 2 trial be rapidly conducted with alisporivir in patients with SARS-CoV-2 infection.




2

Oops! Microsoft Briefly Leaked 250M Customer Support Records

The records involved conversation logs between Microsoft support agents and customers across the globe, dating back to 2005. Most of the records were redacted of customer contact information, but not all.




2

The Best Parental Control Software for 2020

Parenting styles run the gamut and so do the features in parental control and monitoring utilities. We've tested the top hardware- and software-based services to help you choose the right one for your family.




2

The Best Free Antivirus Protection for 2020

Windows Defender is improving, but you still shouldn't rely on Windows 10's security tools as your sole means of protection. Many free third-party security apps are more effective at keeping you safe. We've tested 17 no-cost services to help you find the best free antivirus for protecting your PC.




2

Fin24.com | JSE wrap | Oil price drop drives further stock pessimism

The JSE fell on Tuesday as global markets tumbled on the back of a rout in crude oil prices.




2

Fin24.com | Brent crude oil drops to 21-year low as selling pressure intensifies

"The entire energy market is still on a knife edge," says an economist.




2

Fin24.com | JSE wrap | Local stocks firmer as inflation slows

The local bourse inched higher on Wednesday as global stocks took a breather following consecutive sessions of weakness.




2

Fin24.com | JSE wrap | Surge as global sentiment remains optimistic

Local stocks advanced for a second consecutive session on Thursday as global markets remained resurgent.




2

Fin24.com | Oil prices roar back on US-Iran tensions

Oil prices made a spectacular comeback Thursday as fresh US-Iran tensions erupted, also helping equities advance after US labour market figures provided a glimmer of hope for the world's top economy.




2

Fin24.com | Stocks struggle as antiviral drug hopes fade

Stock markets struggled on Friday as hopes of quickly finding a treatment for coronavirus were dashed, analysts said, and more crushing economic data delivered a body blow to confidence.




2

Fin24.com | Stock markets rally on virus hopes, but oil tanks

Equity markets have rallied Monday as countries eased coronavirus lockdown measures, but oil prices tumbled as a supply glut offset output cuts.




2

Fin24.com | Gold falls as moves to reopen economies erode appetite for havens

The precious metal eased for a third day after US equities hit the highest in almost seven weeks as states including Florida took steps toward easing restrictions.




2

Fin24.com | Local bourse firms as global economies gear for partial reopening

Global markets rallied on the back of optimism that most governments were gearing up to at least partially reopen their economies following lockdowns to prevent the spread of the coronavirus.




2

Fin24.com | Positive virus drug trial news spurs stocks

The surge in stocks was on the back of positive news from trials being conducted on a potential treatment for the coronavirus. With most economies looking to partially reopen their economies, this brought a jump across most asset classes including commodities.




2

Fin24.com | SA stocks are on track for a record month

Unprecedented demand for online services and entertainment during the Covid-19 pandemic lockdowns, along with a scramble for haven investments, have helped set South African stocks on course for a record month.




2

Fin24.com | JSE erases earlier gains as global economy exhibits more strain

The local bourse had managed to open firmer following a rally in Asian stocks in earlier trading.




2

Fin24.com | Stock markets plunge on devastating growth data

Stock markets plunged on Thursday after economic growth data confirmed fears of Covid-19's bruising impact on the world economy.




2

Fin24.com | Gold bars fight coronavirus kits for space on the plane

Swiss refiner Valcambi SA tried for five straight days last month to move a shipment of gold out of Hong Kong. Twice the metal was packed carefully onto a plane, only to be offloaded again.




2

Fin24.com | Markets wrap | JSE retreats as global markets fret over economic growth

Deep losses were recorded across most European benchmarks except the FTSE 100 which managed to trade relatively flat on the day.




2

Fin24.com | Oil rises for a fifth day with output cuts easing glut concern

Oil was headed for the longest run of daily gains in more than nine months on signs the worst of the supply glut may be over as production cuts start to take effect.




2

Fin24.com | Markets wrap | Firmer close in Asia lifts JSE All-Share Index

On the currency market, the rand traded softer against the greenback as it slipped to a session low of R18.77/$.




2

Fin24.com | Markets wrap | Local stocks edge higher as optimism remains

Still, there was disappointment in terms of economic data following the release of the SACCI Business Confidence index data for April which came in at 77.8, compared to a forecast of 89.2.




2

Fin24.com | Oil set for second weekly gain with market starting to rebalance

Oil headed for its first back-to-back weekly gain since February as output cuts from the biggest producers and a nascent recovery in demand began to rebalance a market awash with crude.




2

Fin24.com | Stocks rise despite record US job losses

The rand strengthened against the greenback as it peaked at a session high of R18.30 before it was recorded trading 1.41% firmer at R18.32/$ at 17.00




2

Education Is the Darling of Wealthy Philanthropists, But K-12 Is Losing Its Luster

Around the world, education is the largest recipient of philanthropic giving by a large margin, but in the United States, funders are moving away from investing in K-12 schools in favor of early childhood and higher education.




2

Philanthropy Roundtable K-12 Chief on Funders' Response to Coronavirus

"This pandemic has given us an opportunity to think boldly about students' educational needs and how to creatively respond to them," says Katherine Haley.




2

Pediatric Orphan Drug Indications: 2010-2018

BACKGROUND:

Orphan drug development is crucial for children, who are disproportionately affected by rare diseases. Data are lacking on the number, nature, and benefit of recently approved pediatric orphan indications.

METHODS:

We classified the 402 orphan indications the US Food and Drug Administration approved between 2010 and 2018 as "pediatric" if they were approved for children only or targeted pediatric diseases. We determined the number of unique diseases targeted by pediatric orphan indications and calculated the proportion that were for (1) novel drugs, (2) non-novel drugs approved to treat ≥1 common disease, and (3) non-novel drugs approved only to treat rare diseases. Among pediatric orphan indications eligible for US Food and Drug Administration breakthrough designation (granted to drugs potentially representing major therapeutic advances), we calculated the proportion receiving this designation.

RESULTS:

Of the 402 orphan indications, 136 (33.8%) were pediatric. These 136 indications targeted 87 unique diseases; 21 diseases were targeted by ≥1 indication. Of the 136 pediatric orphan indications, 60 (44.1%) were for novel drugs, 45 (33.1%) were for non-novel drugs approved to treat ≥1 common disease, and 31 (22.8%) were for non-novel drugs approved only to treat rare diseases. Among 97 indications eligible for breakthrough designation, 20 (20.6%) received this designation.

CONCLUSIONS:

Recent orphan drug development has increased the availability of treatments for pediatric rare diseases. Most pediatric orphan indications expanded use of existing drugs, and many targeted the same disease. Some indications may represent breakthroughs, but substantial unmet need for treatments remains for most pediatric rare diseases.




2

Trends in Pediatricians Developmental Screening: 2002-2016

BACKGROUND:

Current guidelines from the American Academy of Pediatrics recommend screening children for developmental problems by using a standardized screening tool and referring at-risk patients to early intervention (EI) or subspecialists. Adoption of guidelines has been gradual, with research showing many children still not being screened and referred.

METHODS:

We analyzed American Academy of Pediatrics Periodic Survey data from 2002 (response rate = 58%; N = 562), 2009 (response rate = 57%; N = 532), and 2016 (response rate = 47%, N = 469). Surveys included items on pediatricians’ knowledge, attitudes, and practices regarding screening and referring children for developmental problems. We used descriptive statistics and a multivariable logistic regression model to examine trends in screening and referral practices and attitudes.

RESULTS:

Pediatricians’ reported use of developmental screening tools increased from 21% in 2002 to 63% in 2016 (P < .001). In 2016, on average pediatricians reported referring 59% of their at-risk patients to EI, up from 41% in 2002 (P < .001), and pediatricians in 2016 were more likely than in 2002 to report being "very likely" to refer a patient with global developmental delay, milestone loss, language delay, sensory impairment, motor delays, and family concern to EI.

CONCLUSIONS:

Pediatricians’ reported use of a standardized developmental screening tool has tripled from 2002 to 2016, and more pediatricians are self-reporting making referrals for children with concerns in developmental screening. To sustain this progress, additional efforts are needed to enhance referral systems, improve EI programs, and provide better tracking of child outcomes.




2

Trends in Pediatric Malpractice Claims 1987-2015: Results From the Periodic Survey of Fellows

BACKGROUND:

Pediatricians are less frequently sued than other physicians. When suits are successful, however, the average payout is higher. Little is known about changes in the risk of litigation over time. We sought to characterize malpractice lawsuit trends for pediatricians over time.

METHODS:

The Periodic Survey is a national random sample survey of American Academy of Pediatrics members. Seven surveys between 1987 and 2015 asked questions regarding malpractice (n = 5731). Bivariate and multivariable analyses examined trends and factors associated with risk and outcome of malpractice claims and lawsuits. Descriptive analyses examined potential change in indemnity amount over time.

RESULTS:

In 2015, 21% of pediatricians reported ever having been the subject of any claim or lawsuit, down from a peak of 33% in 1990. Report of successful outcomes in the most-recent suit trended upward between 1987 and 2015, greatest in 2015 at 58%. Median indemnity was unchanged, averaging $128 000 in 2018 dollars. In multivariate analysis, male sex, hospital-based subspecialty (neonatology, pediatric critical care, pediatric emergency medicine, and hospital medicine), longer career, and more work hours were associated with a greater risk of malpractice claim.

CONCLUSIONS:

From 1987 to 2015, the proportion of pediatricians sued has decreased and median indemnity has remained unchanged. Male pediatricians and hospital-based subspecialists were more likely to have been sued. Greater knowledge of the epidemiology of malpractice claims against pediatricians is valuable because it can impact practice arrangements, advise risk-management decisions, influence quality and safety projects, and provide data to guide advocacy for appropriate tort reform and future research.




2

Igloohome Deadbolt 2S

The Igloohome Deadbolt 2S allows you to lock and unlock your door using your phone, a touch-screen keypad, or physical keys, though it lacks many of the features that you get with similarly priced smart locks.




2

Liverpool v Atlético facts

An early Saúl Ñíguez goal in Madrid means holders Liverpool once again face a second-leg deficit against Spanish visitors.




2

Penn State Smeal names spring 2020 Senior Award honorees

The Penn State Smeal College of Business has announced the recipients of its spring 2020 Senior Awards.




2

Leadership comes naturally to Penn State Smeal spring 2020 student marshal

Jake Griggs, who will graduate Saturday with a 3.95 GPA with dual majors in management and political science, has been named Smeal’s spring 2020 management and organization student marshal.




2

Penn State Lehigh Valley announces 2020 student life and athletics award winners

Students celebrated for athletic and student life achievements during the Finally Finished Fest




2

Fin24.com | Credit ombud rakes in millions for consumers

Are you unhappy with your credit provider? Have you been given more debt than you can afford to pay back? Help is at hand, and it’s just an SMS away.




2

Fin24.com | INFOGRAPHIC: How to get a pay rise

Timing, preparation and control are essential to getting paid fairly. This infographic by Adzuna is guide on how you can navigate your way to a salary increase.




2

Fin24.com | What you need to know when selling or buying

The onus is on you to uncover any defects before you buy, writes Angelique Ruzicka.




2

Fin24.com | SIM-swap scams: How Vodacom protects you

SIM-swap fraud complaints seem to be on the rise with a growing number of victims coming forward to share their dreadful experiences. Vodacom offers some helpful tips.




2

Fin24.com | Beware of cowboy builders

Your smooth-talking builder may promise you the world, but you could end up in a world of pain, writes Angelique Ruzicka.




2

Fin24.com | REVEALED: Africa's wealthiest and poorest people

Mauritians are Africa's wealthiest individuals, while Zimbabweans count as the poorest, according to the latest Africa Wealth Report.




2

Fin24.com | Watch out for loan scam, warns Sanlam

Unsuspected consumers are being targeted by fraudsters using the name of Sanlam to swindle cash out of them, the financial service provider has warned.




2

Fin24.com | Gauteng, Western Cape and KZN top list for card fraud

Gauteng, the Western Cape and KwaZulu-Natal are the hot spots for card fraud in South Africa, according to a report on global fraud activity.




2

Fin24.com | SA inequality grows as rich take larger share - report

New research has found that inequality in SA has increased, with wealth becoming ever more concentrated among the rich.




2

Fin24.com | South Africans are big borrowers and poor savers - expert

Reducing indebtedness and improving savings in South Africa is a major socio-economic challenge, warns an industry expert.




2

Fin24.com | FSB to start scam adverts

Despite the many investment scams that the South African public is falling for, in many cases the Financial Services Board (FSB) finds its hands tied when it comes to protecting the public.




2

Fin24.com | Debit order fraud: Beware of sharing your banking details

Payments Association of South Africa has warned consumers to be cautious when sharing personal information which can be used by fraudsters to make unauthorised debit orders.




2

Fin24.com | Debit fraud: Here is how SA's big 4 banks are handling it

For bank account holders who have been victims of debit order fraud, the big four banks share their remedies.




2

Fin24.com | Debit order fraud: Consumers 'frustrated' and 'annoyed' with banks

Fin24 users speak of their frustrations with banks, calling for a crackdown on debit order fraud that sees payments they didn't authorise being deducted from their bank accounts each month.